Biopharmaceutical company developing next-generation immunotherapies for cancer, inflammation, and autoimmune diseases using computational de novo protein design
Biopharmaceutical company developing next-generation immunotherapies for cancer, inflammation, and autoimmune diseases using computational de novo protein design. Its lead candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha-receptor binding. Neoleukin later became Neurogene through a 2023 reverse merger.